BSC


The increased adoption of bispecific antibodies is being propelled by encouraging results demonstrating efficacy against intractable targets. Oncology and immunotherapy are the best examples of employing novel functionality over existing approaches. This meeting will review preclinical and clinical data and investigate tools and strategies for advancing molecules to the clinic. Plan to attend to hear from leaders in the community who will share last data and insights on drug development with bispecific antibodies.

Topics to be explored include:  

  • Review advance of bispecifics and combination therapy through the clinic
  • Combine antibody-drug conjugates with bispecifics
  • Modulate immune function with bispecifics
  • Appraise strategies for T cell activation
  • Optimize targeting of bispecific antibodies
  • Minimize safety concerns
  • Target checkpoint regulation
  • Deal with immunogenicity and toxicity

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract.  Remember to specify the conference that you are interested in and please provide your full contact information.

The deadline for submission is Friday, September 25, 2015.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.  Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Christina Lingham
Executive Director, Conferences
Phone: 781-972-5464
E: clingham@healthtech.com    

Jason Gerardi
(Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com

Carol Dinerstein
(Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471
E: dinerstein@healthtech.com